TRV GP Iv, LLC

In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 9, 2025), TRV GP Iv, LLC reported 3 stock positions worth $92.9 million. Its top holding was Maze Therapeutics (MAZE) at 72.0% of the portfolio, followed by Tango Therapeutics (TNGX, 24.9%) and Pliant Therapeutics (PLRX, 3.1%). Compared with Q4 2024, it opened 1 new position. The biggest buy was a new position in Maze Therapeutics (MAZE).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001688325
Portfolio Value
$92.9M (Q1 2025)
SEC Filing
0000950123-25-004486 ↗ filed May 9, 2025

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $206.4M Q1 2024 Q2 2024: $202.2M Q2 2024 Q3 2024: $162.1M Q3 2024 Q4 2024: $80.2M Q4 2024 Q1 2025: $92.9M $92.9M Q1 2025 Q2 2025: $163.3M Q2 2025 Q3 2025: $274.0M Q3 2025 Q4 2025: $255.1M Q4 2025 Q1 2026: $266.9M Q1 2026 Q2 2026: $253.7M Q2 2026

Holdings 3 stocks · $92.9M
MAZE Maze Therapeutics Inc. 72.02% 6,073,958 $66.9M New
TNGX Tango Therapeutics Inc. 24.88% 16,859,075 $23.1M No change
PLRX Pliant Therapeutics Inc. 3.10% 2,132,867 $2.9M No change

Portfolio Sells Q4 2024 → Q1 2025
None this quarter.

Portfolio Buys Q4 2024 → Q1 2025
MAZE Maze Therapeutics Inc. New 72.02% +72.02

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$253.7MMAZE, TNGX
Q1 2026 2$266.9MMAZE, TNGX
Q4 2025 2$255.1MMAZE, TNGX
Q3 2025 2$274.0MMAZE, TNGX
Q2 2025 3$163.3MTNGX, MAZE, PLRX
Q1 2025 3$92.9MMAZE, TNGX, PLRX
Q4 2024 2$80.2MTNGX, PLRX
Q3 2024 3$162.1MTNGX, PLRX, FULC
Q2 2024 3$202.2MTNGX, PLRX, FULC
Q1 2024 3$206.4MTNGX, PLRX, FULC